Events

Dr Ben Davis is an NMR spectroscopist and biophysicist by training, although since 2022 he has focussed on Business Development. However, he still maintains an active interest in developing new methods to enable Fragment Based Drug Discovery, particularly against challenging targets. Ben studied for his PhD in protein folding with Professor Alan Fersht at Cambridge University, and then studied molecular interactions at UCL before joining RiboTargets, now Vernalis, in 1998. He has contributed to seven books on FBDD since 2012, and has been an author on more than thirty scientific publications. He is a frequent speaker at scientific conferences.

Lee Walmsley has been with Vernalis since 2001 and, prior to that, was with Roche for 9 years. Lee has led successful drug discovery projects in collaboration with our partners based in Europe, USA and Japan. He is a champion of bringing new methodologies to our chemistry group. Leading a small technology team, he has established our flow chemistry capabilities and augmented this with state of the art organometallic, electrochemical, redox and photocatalytic chemistry.